IOL CHEMICALS & PHARMACEUTICALS LTD. Q1 FY26 Results
IOLCPQ1 FY26 ResultsAnnounced 7 Aug 2025, 02:30 pm| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 551.69 | 4.5% |
| Total Income | 559.06 | 5.0% |
| Expenditure | 513.55 | 5.3% |
| PBT | 45.51 | 1.8% |
| Net Profit | 33.93 | 8.0% |
| OPM | 11.26% | 0.63pp |
| NPM | 6.07% | 0.17pp |
| EPS | 1.16 | 8.4% |
IOL Chemicals & Pharmaceuticals Reports Robust Q1 FY26 Performance
07 Aug 2025 · 7 Aug 2025, 06:43 pm
Summary
IOL Chemicals & Pharmaceuticals Ltd. has reported its financial results for the quarter ended 30th June 2025, showing growth in revenue, EBITDA, and PAT. The company's revenue from operations stands at 551.7 Cr, EBITDA at 69.5 Cr, and PAT at 34.0 Cr. The company has also initiated a project to set up a dedicated manufacturing unit for Minoxidil and its intermediates.
Key Highlights
- 1
Revenue from Operations: 551.7 Cr (9.8% Y-o-Y growth)
- 2
EBITDA: 69.5 Cr (19.5% Y-o-Y growth)
- 3
PAT: 34.0 Cr (14.4% Y-o-Y growth)
- 4
Cash Profit After Tax: 54.8 Cr (16.0% Q-o-Q growth)
- 5
Successfully obtained REACH registration under EU regulations for Acetic Anhydride
- 6
Initiated a 5.5 crore project to set up Unit 9B for dedicated manufacturing of Minoxidil and its intermediates
- 7
Majority of non-lbuprofen APIs are operating at utilization levels of 65-70%+
- 8
Earned EcoVadis Silver Medal
Management Comments
Mr Vikas Gupta
Joint Managing Director
We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, IOL has delivered impressive performance, underscoring the resilience of our integrated business model.
Informational and educational content only. Not investment advice.